Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hank cetuximab combinations and methods

A composition and antibody technology, applied in chemical instruments and methods, biochemical equipment and methods, drug combinations, etc., can solve the problems that have not yet been used in combination with doxorubicin and immunotherapeutic agents

Pending Publication Date: 2020-04-10
河谷细胞有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Notably, doxorubicin has not been compared with immunotherapy, possibly due to suspected adverse effects due to DNA damage responses and epigenetic and transcriptomic dysregulation in various cells exposed to doxorubicin. Combination of therapeutic agents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hank cetuximab combinations and methods
  • Hank cetuximab combinations and methods
  • Hank cetuximab combinations and methods

Examples

Experimental program
Comparison scheme
Effect test

example I

[0055] Example I: Immunotherapy of a patient with advanced chordoma

[0056] Therapeutic compositions and modalities used in Example I include various biomolecules and compositions shown in Table 1 below.

[0057]

[0058]

[0059] Table 1

[0060] Treatment was administered in 2 phases, an induction phase and a maintenance phase, as described below. Subjects continued induction therapy for up to 1 year, or until they experienced progressive disease (PD) or unacceptable toxicity (not correctable by dose reduction). Those patients with a complete response (CR) during the induction phase entered the maintenance phase of the study. Subjects may remain in the maintenance phase of the study for a maximum of 1 year. Treatment continued in the maintenance phase until subjects experienced PD or unacceptable toxicity (uncorrectable by dose reduction). The maximum duration of study treatment (including both induction and maintenance phases) was 2 years.

[0061] Tumor biopsie...

example II

[0080] Example II: NANT Squamous Cell Carcinoma (SCC) Vaccines: Molecular Information Integrative Immunotherapy Combining Innate High-Affinity Natural Killer (haNK) Cell Therapy with Adenovirus and Yeast-Based Vaccines T-cell responses in subjects with SCC who progressed on or after cytodeath protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) therapy.

[0081] Therapeutic compositions and modalities used in Example II include various biomolecules and compositions shown in Table 2 below.

[0082]

[0083]

[0084] Table 2

[0085] Treatment in this example is offered to patients who were previously treated with platinum-based chemotherapy and anti-PD-1 / PD-L1 therapy and whose tumors progressed on or after platinum-based chemotherapy and anti-PD-1 / PD-L1 therapy. Treatment in this example was administered in 2 phases, an induction phase and a maintenance phase, as described below. Subjects continued induction therapy for a maximum of 1 year. Those patients with a complet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

Description

[0001] This application claims priority to our co-pending US Provisional Application with Serial No. 62 / 545,744 filed August 15, 2017, which is incorporated herein in its entirety. technical field [0002] The field of the invention is compositions and methods for cancer treatment, especially when the cancer treatment involves the combination of an immunotherapy drug with a targeted form of doxorubicin. Background technique [0003] The following description includes information useful for understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is any publication specifically or implicitly referenced to be prior art. [0004] All publications identified herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. To the extent that a def...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K31/704A61K39/395A61K45/06A61P35/00
CPCA61K45/06A61K31/704A61P35/00A61K39/3955A61K39/39558C07K16/22C07K16/2818C07K16/2827C07K16/2863A61K2039/505A61K2039/507A61K2039/545A61K2039/852A61K2039/523A61K2039/5256C12N2710/10043A61K39/464452A61K2239/31A61K2239/54A61K39/464482A61K39/464406A61K39/4613A61K2239/38A61K39/46447A61K39/464464A61K2300/00A61K2039/585A61K31/7056A61K2039/55522A61P31/00A61K39/001152A61K39/001164A61K39/00117A61K39/001182
Inventor 派翠克·松吉翁
Owner 河谷细胞有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com